By Nick Paul Taylor
Orgenesis has struck a deal to acquire Koligo Therapeutics. The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.
read more
By Kyle Blankenship
With all eyes on the hunt for a COVID-19 vaccine, drugmakers like New Jersey's Johnson & Johnson are scouring the market for manufacturing partners to help meet what would be global demand for their shots. With a couple already in hand, J&J is now turning to a Michigan CDMO to help keep up.
read more
By Paige Minemyer
Here's a look at the status of some of the benefits—such as telehealth coverage—that major national insurers rolled out earlier this year.
read more
By Conor Hale
The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.
read more
By Paige Minemyer
Blue Cross and Blue Shield of North Carolina is teaming up with prominent providers and companies in the state to manufacture N95 respirators for healthcare workers.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Serum Institute of India will churn out 100 million more vaccine doses for distribution through COVAX. Orgenesis snagged a COVID-19 cell therapy through its Koligo acquisition. Windtree got the OK to launch a phase 2 trial of its synthetic surfactant. And Russia is gearing up to release interim phase 3 vaccine data.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
